Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds

Researchers reported in Nature Medicine that direct brain monitoring of a patient receiving tirzepatide (Mounjaro/Zepbound) showed a temporary suppression of nucleus accumbens “food‑craving” signals and absence of food preoccupation, marking the first in‑person neural measurement of the drug’s impact; the signal suppression waned after about five months and other trial participants not on tirzepatide continued to show elevated reward‑center activity. The single‑patient nature of the report prevents generalization, but the result suggests GLP‑1/glucose‑dependent therapies can affect reward circuitry and may prompt R&D into versions optimized for treating binge‑eating or other compulsive eating disorders rather than solely diabetes/weight loss.

Analysis

Researchers reported in Nature Medicine the first direct in‑person neural measurement of tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss), observing that a single patient with severe binge‑eating experienced temporary suppression of nucleus accumbens "food‑craving" signals and an absence of food preoccupation during the initial months of monitoring. The observation occurred in the context of a first‑in‑human deep‑brain stimulation trial for loss‑of‑control eating; the patient had been prescribed tirzepatide prior to electrode implantation while other trial participants not on the drug continued to show elevated reward‑center activity. Researchers observed the drug’s effect waned after about five months, with nucleus accumbens activity and severe food preoccupation returning, leading investigators to conclude the effect was temporary in this case. Investigators caution the finding is a single‑patient signal that cannot be generalized but suggests GLP‑1/glucose‑dependent therapies can influence reward circuitry and may create longer‑term R&D optionality for treatments targeting binge‑eating if molecules are redesigned to act on the reward center, while near‑term market impact appears limited amid a mixed/cautious market sentiment.

Key Decisions for Investors

• Do not materially reweight positions in Eli Lilly based on this single‑patient report; await replication in larger, controlled studies before assuming clinical or commercial impact
• Monitor for formal trial initiations, Nature Medicine follow‑ups, and any Eli Lilly disclosures about neuropsychiatric indications or dedicated R&D programs targeting nucleus accumbens signaling, and treat such announcements as the critical catalyst
• If maintaining or adding exposure to LLY for GLP‑1 franchise upside, size positions conservatively and consider hedging near‑term given the temporary effect observed and current mixed market sentiment